Payment overview · 2025
General Payments
$942.09
49 reported records · 7 companies
Healthcare provider profile · identity verified
Leslie Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ALHAMBRA, CA · NPI 1790830156
Verified facts
What the public records show
CMS Open Payments records show Leslie Lee, M.D. received $942.09 in general payments during 2025 across 49 reported records.
Amgen Inc. accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Kerendia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $357.54 | 38.0% | 28 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $184.05 | 19.5% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $146.25 | 15.5% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.86 | 11.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.09 | 9.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.82 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.48 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $942.09 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $345.66 | 26 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $345.66 | 26 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $184.05 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $146.25 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $80.16 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.03 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.03 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $33.06 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.82 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $11.88 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 57 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
157 | 82 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 394 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 54 |
| Repatha Sureclick | Evolocumab | 221 | 40 |
| Montelukast Sodium | Montelukast Sodium | 213 | 48 |
| Prolia | Denosumab | 157 | 82 |
| Ezetimibe | Ezetimibe | 151 | 39 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 133 | 78 |
| Azithromycin | Azithromycin | 114 | 72 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 21 |
| Atorvastatin Calcium | Atorvastatin Calcium | 90 | 25 |
| Pregabalin | Pregabalin | 85 | 26 |
| Alendronate Sodium | Alendronate Sodium | 82 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 81 | 15 |
| Simvastatin | Simvastatin | 81 | 16 |
| Metformin Hcl | Metformin Hcl | 80 | 21 |
| Trazodone Hcl | Trazodone Hcl | 66 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 64 | 13 |
| Clonidine Hcl | Clonidine Hcl | 59 | 14 |
| Lidocaine | Lidocaine | 58 | suppressed |
| Creon | Lipase/Protease/Amylase | 57 | 16 |
| Allopurinol | Allopurinol | 56 | 14 |
| Atenolol | Atenolol | 56 | 17 |
| Colesevelam Hcl | Colesevelam Hcl | 52 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 52 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 12 |
| Vascepa | Icosapent Ethyl | 45 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 13 |
| Levofloxacin | Levofloxacin | 42 | 36 |
| Linzess | Linaclotide | 42 | suppressed |
| Praluent Pen | Alirocumab | 42 | suppressed |
| Mupirocin | Mupirocin | 40 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 39 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 12 |
| Omeprazole | Omeprazole | 34 | 11 |
| Saxagliptin Hcl | Saxagliptin Hcl | 33 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 32 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 32 | 25 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 29 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 30 | 11 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | suppressed |
| Baclofen | Baclofen | 25 | 13 |
| Gabapentin | Gabapentin | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 13 |
| Carvedilol | Carvedilol | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 21 |
| Restasis | Cyclosporine | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Kerendia | Finerenone | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lisinopril | Lisinopril | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $942.09 · 49 records | Amgen Inc. | BREZTRI, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, Kerendia, LEQVIO, OTEZLA, QULIPTA, REPATHA, UBRELVY, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error